再発性／難治性（R/R）急性骨髄性白血病（AML）の成人患者を対象とした、静脈内（IV）投与されたABBV-787の有害事象および動態を評価する試験

基本情報

NCT ID

NCT06068868

ステータス

中止

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

36

治験依頼者名

AbbVie

概要

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. This study is to evaluate how safe ABBV-787 is and how it moves within the body in adult participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). Adverse events and maximum tolerated dose (MTD) of ABBV-787 will be assessed. ABBV-787 is an investigational drug being developed for the treatment of AML. Participants will receive ABBV-787 in escalating doses until the maximum tolerated dose (MTD) is determined. Approximately 60 adult participants with a diagnosis of AML will be enrolled worldwide. Participants will receive intravenous (IV) infusions of ABBV-787 during the approximately 3 year duration a participant is followed. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)